Trial Outcomes & Findings for Interstitial Cystitis: Examination of the Central Autonomic Network (NCT NCT03008382)
NCT ID: NCT03008382
Last Updated: 2025-02-17
Results Overview
The total GUPI score is calculated from the sum of the 3 scores from the subscales. There is no uniformity in the ranges of scores for the individual questions. The 3 subscales are: pain, urinary, and quality of life. The total score range can go from 0-45. The higher the score indicates more female urinary symptoms. Scores were calculated for each participant at weeks 4 (baseline), 12 (post-first intervention) and 24 (post-second intervention) of their participation in the study.
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
72 participants
Primary outcome timeframe
Weeks 4, 12 and 24
Results posted on
2025-02-17
Participant Flow
The study was modified to report data for participants with IC/BPS and MPP as a single combined chronic pelvic pain group. Please review the pre-assignment details sections to view how participants are being presented in for this group.
Participants enrolled into the Chronic Pain Group were randomized into 2 sequences or were enrolled into the observational study group: "Metopropol then Placebo," "Placebo then Metopropol OR "Observational Participants." The "participant flow" and "baseline characteristics" sections for the Chronic Pain Group are presented per sequence.
Participant milestones
| Measure |
Metoprolol Then Placebo
Participants will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet followed by a 4-Week washout period, and then 8 weeks of Placebo.
|
Placebo Then Metoprolol
Participants will be randomized to take 8 weeks of Placebo followed by a 4-Week washout period, and then 8 weeks of Metoprolol Tartrate Oral Tablet.
|
Healthy Control
Healthy female subjects ages 18-80 with various demographic background who do not have any exclusionary diagnostic or symptomatic criteria will be recruited. Subjects will never receive any randomization or drug treatment during the entire duration of the study Placebo Oral Tablet: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
|
Observational Participants
Participants who meet the study eligibility criteria but were not randomized into the two interventional sequences. Participants were not randomized and did not receive any study drugs during the entire duration of the study.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
23
|
22
|
23
|
4
|
|
Overall Study
COMPLETED
|
20
|
16
|
18
|
4
|
|
Overall Study
NOT COMPLETED
|
3
|
6
|
5
|
0
|
Reasons for withdrawal
| Measure |
Metoprolol Then Placebo
Participants will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet followed by a 4-Week washout period, and then 8 weeks of Placebo.
|
Placebo Then Metoprolol
Participants will be randomized to take 8 weeks of Placebo followed by a 4-Week washout period, and then 8 weeks of Metoprolol Tartrate Oral Tablet.
|
Healthy Control
Healthy female subjects ages 18-80 with various demographic background who do not have any exclusionary diagnostic or symptomatic criteria will be recruited. Subjects will never receive any randomization or drug treatment during the entire duration of the study Placebo Oral Tablet: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
|
Observational Participants
Participants who meet the study eligibility criteria but were not randomized into the two interventional sequences. Participants were not randomized and did not receive any study drugs during the entire duration of the study.
|
|---|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
2
|
5
|
2
|
0
|
|
Overall Study
Protocol Violation
|
1
|
0
|
0
|
0
|
|
Overall Study
Withdrew from study but did not withdraw consent
|
0
|
1
|
0
|
0
|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
1
|
0
|
|
Overall Study
Screenfail
|
0
|
0
|
2
|
0
|
Baseline Characteristics
Interstitial Cystitis: Examination of the Central Autonomic Network
Baseline characteristics by cohort
| Measure |
Metoprolol Then Placebo
n=23 Participants
Participants will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet followed by a 4-Week washout period, and then 8 weeks of Placebo.
|
Placebo Then Metoprolol
n=22 Participants
Participants will be randomized to take 8 weeks of Placebo followed by a 4-Week washout period, and then 8 weeks of Metoprolol Tartrate Oral Tablet.
|
Healthy Control
n=23 Participants
Healthy female subjects ages 18-80 with various demographic background who do not have any exclusionary diagnostic or symptomatic criteria will be recruited. Subjects will never receive any randomization or drug treatment during the entire duration of the study.
|
Observational Participants
n=4 Participants
Participants who meet the study eligibility criteria but were not randomized into the two interventional sequences. Participants were not randomized and did not receive any study drugs during the entire duration of the study.
|
Total
n=72 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
23 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
22 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
70 Participants
n=21 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
|
Sex: Female, Male
Female
|
23 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
23 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
72 Participants
n=21 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
12 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
36 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
10 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
15 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
34 Participants
n=21 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
|
Race (NIH/OMB)
White
|
12 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
33 Participants
n=21 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
10 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
15 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
34 Participants
n=21 Participants
|
|
Region of Enrollment
United States
|
23 participants
n=5 Participants
|
22 participants
n=7 Participants
|
23 participants
n=5 Participants
|
4 participants
n=4 Participants
|
72 participants
n=21 Participants
|
PRIMARY outcome
Timeframe: Weeks 4, 12 and 24Population: This assessment was not administered to all participants at each time point.
The total GUPI score is calculated from the sum of the 3 scores from the subscales. There is no uniformity in the ranges of scores for the individual questions. The 3 subscales are: pain, urinary, and quality of life. The total score range can go from 0-45. The higher the score indicates more female urinary symptoms. Scores were calculated for each participant at weeks 4 (baseline), 12 (post-first intervention) and 24 (post-second intervention) of their participation in the study.
Outcome measures
| Measure |
Metoprolol Then Placebo
n=21 Participants
Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol. This intervention aims at determining whether Metoprolol reduces pain in subjects in both groups compared to placebo.
Metoprolol Tartrate Oral Tablet: Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Placebo Oral Tablet: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
|
Placebo Then Metoprolol
n=21 Participants
Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol. This intervention aims at determining whether Metoprolol reduces pain in subjects in both groups compared to placebo.
Metoprolol Tartrate Oral Tablet: Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Placebo Oral Tablet: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
|
Healthy Control
n=17 Participants
Healthy female subjects ages 18-80 with various demographic background who do not have any exclusionary diagnostic or symptomatic criteria will be recruited. Subjects will never receive any randomization or drug treatment during the entire duration of the study
|
Observational Participants
n=4 Participants
Participants who meet the study eligibility criteria but were not randomized into the two interventional sequences. Participants were not randomized and did not receive any study drugs during the entire duration of the study.
|
|---|---|---|---|---|
|
Total Score on Genitourinary Pain Index (GUPI) Scale
Week 4
|
24.4 score on a scale
Standard Deviation 8.54
|
22.2 score on a scale
Standard Deviation 8.94
|
2.35 score on a scale
Standard Deviation 2.37
|
29.25 score on a scale
Standard Deviation 7.27
|
|
Total Score on Genitourinary Pain Index (GUPI) Scale
Week 12
|
22.8 score on a scale
Standard Deviation 11.1
|
21.4 score on a scale
Standard Deviation 8.88
|
2.42 score on a scale
Standard Deviation 3.67
|
26.65 score on a scale
Standard Deviation 9.84
|
|
Total Score on Genitourinary Pain Index (GUPI) Scale
Week 24
|
23.1 score on a scale
Standard Deviation 12
|
22.1 score on a scale
Standard Deviation 7.8
|
1.67 score on a scale
Standard Deviation 1.15
|
—
|
PRIMARY outcome
Timeframe: Weeks 4, 12 and 24Population: This assessment was not administered to all participants at each time point.
The average score comes from the Pain Experience, the first domain, of the MPI. Domain 1 includes five scales designed to measure important dimensions of the chronic pain experience including; 1) perceived interference of pain in vocational, social/recreational, and family/marital functioning, 2) support or concern from spouse or significant other, 3) pain severity, 4) perceived life control, and 5) affective distress. Higher scores indicate more impactful effects of the pain experience in daily life. Responses from individual questions range from 0-6. 0 indicated no pain/no interference/no change. 6 indicates very intense pain/extreme interference/extreme change. The final total score range is 0-6 with 0 being absent pain and 6 being the worst pain rating. A lower score is better. Scores were calculated for each participant at weeks 4 (baseline), 12 (post-first intervention) and 24 (post-second intervention) of their participation in the study.
Outcome measures
| Measure |
Metoprolol Then Placebo
n=22 Participants
Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol. This intervention aims at determining whether Metoprolol reduces pain in subjects in both groups compared to placebo.
Metoprolol Tartrate Oral Tablet: Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Placebo Oral Tablet: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
|
Placebo Then Metoprolol
n=21 Participants
Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol. This intervention aims at determining whether Metoprolol reduces pain in subjects in both groups compared to placebo.
Metoprolol Tartrate Oral Tablet: Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Placebo Oral Tablet: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
|
Healthy Control
n=17 Participants
Healthy female subjects ages 18-80 with various demographic background who do not have any exclusionary diagnostic or symptomatic criteria will be recruited. Subjects will never receive any randomization or drug treatment during the entire duration of the study
|
Observational Participants
n=4 Participants
Participants who meet the study eligibility criteria but were not randomized into the two interventional sequences. Participants were not randomized and did not receive any study drugs during the entire duration of the study.
|
|---|---|---|---|---|
|
Average Score on the First Domain of the Multidimensional Pain Scoring (MPI) Scale
Week 4
|
2.44 score on a scale
Standard Deviation 1.11
|
2.16 score on a scale
Standard Deviation 0.878
|
1.28 score on a scale
Standard Deviation 0.28
|
2.95 score on a scale
Standard Deviation 1.38
|
|
Average Score on the First Domain of the Multidimensional Pain Scoring (MPI) Scale
Week 12
|
2.53 score on a scale
Standard Deviation 1.03
|
1.99 score on a scale
Standard Deviation 0.863
|
1.41 score on a scale
Standard Deviation 0.45
|
2.57 score on a scale
Standard Deviation 1.42
|
|
Average Score on the First Domain of the Multidimensional Pain Scoring (MPI) Scale
Week 24
|
2.35 score on a scale
Standard Deviation 1.14
|
2.11 score on a scale
Standard Deviation 0.747
|
1.13 score on a scale
Standard Deviation 0.35
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 24 WeeksA linear model with connectivity at 24 weeks as outcome, connectivity at baseline as a covariate and change in ANS-R, demographics such as age and group and the interactions of group with other covariate.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline, 12 weeks and 24 weeksThis exploratory aim for the sub-studyused functional MRI brain imaging to examine the evolution of the connectivity of the main autonomic processing nucleus, the periaqueductal gray region, with other cortical brain regions
Outcome measures
Outcome data not reported
Adverse Events
Metoprolol
Serious events: 0 serious events
Other events: 22 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 25 other events
Deaths: 0 deaths
Baseline Period
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Washout Period
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Observational Participants
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Healthy Control
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Metoprolol
n=43 participants at risk
Participants who experienced an adverse event while on the metoprolol intervention.
|
Placebo
n=42 participants at risk
Participants who experienced an adverse event while on the placebo intervention.
|
Baseline Period
n=45 participants at risk
Participants who experienced an adverse event prior to either intervention while on the study. This was during weeks 0-4 of the study.
|
Washout Period
n=40 participants at risk
Participants who experienced an adverse event who were between interventions while on the study. This was during weeks 13-16 of the study.
|
Observational Participants
n=4 participants at risk
Healthy female subjects ages 18-80 with various demographic background who do not have any exclusionary diagnostic or symptomatic criteria will be recruited. Subjects will never receive any randomization or drug treatment during the entire duration of the study.
|
Healthy Control
n=23 participants at risk
Participants who meet the study eligibility criteria but were not randomized into the two interventional sequences. Participants were not randomized and did not receive any study drugs during the entire duration of the study.
|
|---|---|---|---|---|---|---|
|
General disorders
Sleep paralysis + Nightmares
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Infections and infestations
Urinary Tract Infection
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.5%
1/40 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Nervous system disorders
Near Syncopal Event
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Respiratory, thoracic and mediastinal disorders
Chest Tightness
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Gastrointestinal disorders
Nausea and vomiting
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Psychiatric disorders
Depressed mood post 1st round of study medication
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Reproductive system and breast disorders
Yeast infection
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Musculoskeletal and connective tissue disorders
Joint pain
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.5%
1/40 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Renal and urinary disorders
Worsening Bladder Pain
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.2%
1/45 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Skin and subcutaneous tissue disorders
toothache
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.2%
1/45 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Cardiac disorders
low heart rate
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Surgical and medical procedures
Vulvectomy and LEEP
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Product Issues
Reaction to lidocaine
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Social circumstances
Car accident
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.2%
1/45 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Nervous system disorders
Vestibular migraines with vertigo
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.5%
1/40 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Nervous system disorders
Migraine headache
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Nervous system disorders
Valsalva maneuver-headache
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.2%
1/45 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Nervous system disorders
Fibromyalgia flare
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.5%
1/40 • Number of events 2 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma exacerbation
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Respiratory, thoracic and mediastinal disorders
Shortness of breath
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 2 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing with bronchitis
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Gastrointestinal disorders
Diarrhea
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Gastrointestinal disorders
nausea
|
4.7%
2/43 • Number of events 2 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
4.8%
2/42 • Number of events 2 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Gastrointestinal disorders
stomach rash
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Psychiatric disorders
anxiety
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Psychiatric disorders
Heightened mood/depressive symptoms
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Renal and urinary disorders
Bladder flare
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Skin and subcutaneous tissue disorders
skin irritation
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.2%
1/45 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Skin and subcutaneous tissue disorders
electrode reaction
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Skin and subcutaneous tissue disorders
Rash (allergic reaction)
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Skin and subcutaneous tissue disorders
hair loss
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
erratic sleep
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
fatigue
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
7.1%
3/42 • Number of events 3 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Night sweats & changes in mood
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Reproductive system and breast disorders
Sexual dysfunction
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Infections and infestations
Constipation
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Cardiac disorders
Abnormal EKG
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Lightheadedness
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Memory issues
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Psychiatric disorders
Depression
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Dizziness
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Wooziness
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Headache
|
2.3%
1/43 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Infections and infestations
Chills
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
Infections and infestations
Loss of appetite
|
0.00%
0/43 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
2.4%
1/42 • Number of events 1 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
|
General disorders
Sleep problems
|
4.7%
2/43 • Number of events 2 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/42 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/45 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/40 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/4 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
0.00%
0/23 • 24 weeks (duration of study)
Adverse events were divided into 4 categories: Metoprolol, Placebo, Baseline Period (prior to either intervention) and Washout Period (in between the two interventions) for the randomized Chronic Pelvic Pain participants.
|
Additional Information
Dr. Thomas Chelimsky
Virginia Commonwealth University
Phone: (804) 628-4859
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place